世界の乳がん治療薬市場
Market Size in USD Billion
CAGR :
% 
USD
30,247.54 Million
USD
55,996.57 Million
2022
2030
 予測期間 |
2023 –2030 |
 市場規模（基準年） |
USD 30,247.54 Million |
 Market Size (Forecast Year) |
USD 55,996.57 Million |
 CAGR |
% |
| Major Markets Players |
|
世界の乳がん治療薬市場、製品タイプ別（薬物療法、化学療法、標的療法、放射線療法、その他）、がんの種類別（浸潤性乳管がん（IDC）、浸潤性小葉がん（ILC）、炎症性乳がん、乳頭パジェット病、乳房血管肉腫、乳房葉状腫瘍、非浸潤性（原位置）乳がん、乳管上皮内がん（DCIS）、小葉上皮内がん（LCIS）、転移性乳がん、その他）、ステージ別（ステージ 0、ステージ I、ステージ II、ステージ III、ステージ IV）、薬剤タイプ別（ジェネリックおよびブランド）、年齢層別（高齢者および成人）、投与経路別（経口および静脈内）、エンドユーザー別（病院、専門クリニック、がんセンター、その他）、流通チャネル別（病院薬局、小売薬局、オンライン）薬局 - 2030 年までの業界動向と予測。
乳がん治療薬市場の分析と規模
さまざまな国で乳がんの発生率が増加していることが、市場の成長を牽引しています。世界の乳がん治療薬市場は、2023年から2030年の予測期間に市場成長を遂げると予想されています。
データブリッジマーケットリサーチは、世界の乳がん治療薬市場は2022年の302億4,754万米ドルから2030年には559億9,657万米ドルに達し、2023年から2030年の予測期間中に8.2%のCAGRで成長すると分析しています。
|
レポートメトリック |
詳細 |
|
予測期間 |
2023年から2030年 |
|
基準年 |
2022 |
|
歴史的な年 |
2021 (カスタマイズ可能 2015-2020) |
|
定量単位 |
収益（百万米ドル） |
|
対象セグメント |
製品タイプ (医薬品、化学療法、標的療法、放射線療法など)、がんの種類 (浸潤性乳管がん (IDC)、浸潤性小葉がん (ILC)、炎症性乳がん、乳頭パジェット病、乳房血管肉腫、乳房葉状腫瘍、非浸潤性 (原位置) 乳がん、乳管上皮内がん (DCIS)、小葉上皮内がん (LCIS)、転移性乳がんなど)、ステージ (ステージ 0、ステージ I、ステージ II、ステージ III、ステージ IV)、薬剤の種類 (ジェネリックおよびブランド)、年齢層 (高齢者および成人)、投与経路 (経口および静脈内)、エンドユーザー (病院、専門クリニック、がんセンターなど)、流通チャネル (病院薬局、小売薬局、オンライン薬局) |
|
対象国 |
米国、カナダ、メキシコ、ドイツ、フランス、英国、イタリア、スペイン、オランダ、ロシア、スイス、トルコ、その他のヨーロッパ諸国、中国、日本、インド、韓国、オーストラリア、シンガポール、タイ、マレーシア、インドネシア、フィリピン、その他のアジア太平洋諸国、ブラジル、アルゼンチン、その他の南米諸国、南アフリカ、サウジアラビア、アラブ首長国連邦、エジプト、その他の中東およびアフリカ諸国 |
|
対象となる市場プレーヤー |
F. ホフマン・ラ・ロシュ社、ファイザー社、アストラゼネカ社、ノバルティス社、イーライリリー社、メルク社、サノフィ社、ブリストル・マイヤーズ スクイブ社、エーザイ株式会社、マイラン社（ビアトリス社の子会社）、テバ製薬株式会社、協和キリン株式会社、マクロジェニックス社、ギリアド・サイエンシズ社、武田薬品工業株式会社、アッヴィ社。 |
市場の定義
乳がんは、乳房組織内の悪性細胞が抑制されないまま増殖することで発症する病気です。乳がんは、がん細胞を標的にしてその成長を阻止し、腫瘍を縮小し、体の他の部位へのがんの転移を止めるために作られた薬剤で治療できます。これに加えて、放射線療法、化学療法、ホルモン療法など、さまざまな追加治療オプションも利用できます。
乳がんの種類と進行度、特定の分子マーカーの存在、および患者の固有の特徴はすべて、どの乳がん治療薬を使用するかを決定する際に重要な役割を果たします。患者ごとの治療計画は個別に作成され、これらの薬剤の組み合わせが含まれる場合があります。乳がんの薬物療法では、完全な寛解、腫瘍の縮小、または副作用を抑えながら病気の進行を止めるなど、可能な限り最良の結果が求められます。
世界の乳がん治療薬市場の動向
このセクションでは、市場の推進要因、機会、制約、課題について理解します。これらについては、以下で詳しく説明します。
ドライバー
- 乳がん治療に関連する薬剤の進歩
医薬品開発におけるイノベーションは、世界の乳がん治療薬市場を変革する原動力となっており、治療オプションの進歩を促し、患者の転帰を大幅に改善しています。乳がんは、世界的に最も蔓延し、最も致命的ながんの 1 つであるため、医薬品研究開発の重要な焦点となっています。治療法と治療アプローチの継続的な進化により、ケアの質が向上し、市場の成長が促進されています。
乳がん治療薬開発における最も注目すべき革新の 1 つは、標的療法の出現です。これらの薬剤は、個人の腫瘍の分子的および遺伝的特性を特に標的とするように設計されており、より正確で効果的な治療をもたらします。HER2 タンパク質を標的とするハーセプチンや、パルボシクリブなどの CDK4/6 阻害剤などの薬剤の開発は、乳がんの治療に革命をもたらし、生存率の大幅な向上と副作用の軽減につながっています。このように、乳がん治療における薬剤開発の継続的な革新は、患者の転帰の改善とこの壊滅的な病気との闘いにおけるより明るい未来への新たな道を提供し、市場の成長を牽引しています。
- 各国で乳がんの発症率が増加
近年、乳がんの発生率に関連する懸念すべき傾向がさまざまな国で現れています。この増加は、ライフスタイルの変化、食習慣、ホルモンの不均衡、出産の遅れ、平均寿命の延長など、多くの要因の結果です。現代の座りがちなライフスタイル、加工食品の大量消費、身体活動の制限、環境汚染物質への曝露、特定の遺伝的素因の蔓延などが相まって、乳がんの発生率の増加につながっています。
乳がんの発生率の増加は、製薬業界だけでなく、医療制度や政策にも影響を及ぼしています。政府や医療機関は、早期発見プログラム、教育イニシアチブ、スクリーニング キャンペーンを強化する取り組みを強化しています。これらのイニシアチブは、乳がんの負担増大に対処し、タイムリーな診断を確保し、治療への積極的なアプローチを促進する上で非常に重要です。さらに、乳がん治療薬の需要が急増し続ける中、世界中の乳がん患者のための最先端の治療法の開発と利用を加速するために、製薬会社、研究機関、医療提供者間の連携が不可欠になり、これが市場の成長を牽引しています。
機会
- がん研究に対する政府の取り組みとその他の資金源
世界中の政府は、医療と経済の大きな負担を認識し、研究開発への取り組みにいくつかの取り組みと投資を行いました。政府の助成金と資金提供プログラムにより、製薬会社と研究機関は革新的な治療法を研究し、薬の有効性をテストし、新薬を市場に投入することができます。この研究により、より効果的で毒性の少ない乳がん治療薬が発見されることが多く、患者が利用できる治療オプションが拡大します。
政府主導の取り組みでは、一般の啓発キャンペーンやスクリーニング プログラムを通じて、早期発見と予防の重要性を強調しています。これらの取り組みにより、早期診断と介入が可能になり、進行期乳がんの治療にかかる医療費を削減できる可能性があります。さらに、がん研究に重点を置くことで、学界、産業界、医療提供者間の連携が促進され、科学的進歩を患者の実際の治療に応用しやすくなります。
政府の取り組みに加えて、民間および非営利団体もがん研究への資金提供において重要な役割を果たしています。多様な資金源が利用可能であることで、革新的な治療法の開発がさらに促進され、市場はダイナミックで成長している分野となっています。最終的には、政府とさまざまな資金源の協調的な取り組みにより、乳がん治療が改善され、患者の転帰が改善され、市場の成長機会が生まれることが期待されます。
抑制/挑戦
- がん治療に関連する薬剤費の高騰
がん治療に関連する薬剤は高額であることが多く、革新的で標的を絞った治療法が次々と登場する中、患者と医療制度に多大な経済的負担をかけています。
第一に、これらの薬剤の高額な費用が、患者が先進治療を受ける機会を制限しています。効果が実証されているにもかかわらず、ほとんどの患者は治療を受ける余裕がありません。十分な保険に加入していない患者や、これらの高価な薬剤へのアクセスが限られている国の患者は、最も効果的な治療を受けるのに障壁に直面し、乳がん治療の結果に不平等が生じる可能性があります。さらに、財政的負担は医療システムと保険会社にまで及びます。高価な抗がん剤を賄うための予算上の圧力により、他の必須の医療ニーズからリソースが転用される可能性があります。この資金の転用は、医療の公平性と医療システム全体の持続可能性に幅広い影響を及ぼす可能性があります。
さらに、薬価の高騰は患者にとって支払えない出費につながり、経済的毒性を引き起こす可能性があります。患者はこれらの薬が支払えないために治療を遅らせたり忘れたりする可能性があり、それが患者の健康と全体的な予後に悪影響を及ぼす可能性があります。これにより、市場でこれらの薬の需要が減少し、市場の成長が抑制される可能性があります。
世界の乳がん治療薬市場の範囲
世界の乳がん治療薬市場は、製品タイプ、がんの種類、段階、薬の種類、年齢層、投与経路、エンドユーザー、流通チャネルに基づいて、8 つの主要なセグメントに分類されています。
製品タイプ
- 薬
- 化学療法
- 標的療法
- 放射線治療
- その他
製品タイプに基づいて、市場は薬物療法、化学療法、標的療法、放射線療法、その他に分類されます。
がんの種類
- 浸潤性乳管癌（IDC）
- 浸潤性小葉癌（ILC）
- 炎症性乳がん
- 乳頭パジェット病
- 乳房の血管肉腫
- 乳房の葉状腫瘍
- 非浸潤性（原位置）乳がんの種類
- 乳管内癌（DCIS）
- 上皮内小葉癌 (LCIS)
- 転移性乳がん
- その他
がんの種類に基づいて、市場は浸潤性乳管がん（IDC）、浸潤性小葉がん（ILC）、炎症性乳がん、乳頭パジェット病、乳房血管肉腫、乳房葉状腫瘍、非浸潤性（原位置）乳がん、乳管上皮内がん（DCIS）、小葉がん（LCIS）、転移性乳がん、その他に分類されます。
ステージ
- ステージ0
- ステージI
- ステージ II
- ストラーゲIII
- ステージIV
ステージに基づいて、市場はステージ 0、ステージ I、ステージ II、ステージ III、ステージ IV に分類されます。
薬剤の種類
- ジェネリック
- ブランド
医薬品の種類に基づいて、市場はジェネリックとブランドに分類されます。
年齢層
- 老年病
- 大人
年齢層に基づいて、市場は高齢者と成人に分割されます。
投与経路
- オーラル
- 静脈内
投与経路に基づいて、市場は経口と静脈内に分類されます。
エンドユーザー
- 病院
- 専門クリニック
- がんセンター
- その他
On the basis of end user, the market is segmented into hospitals, specialty clinics, cancer centers, and others.
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
On the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy.
Global Breast Cancer Drugs Market Regional Analysis/Insights
The global breast cancer drugs market is analyzed, and market size insights and trends are provided by product type, cancer type, stages, drug type, age group, route of administration, end user, and distribution channel as referenced above.
The countries covered in the this market report are U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Netherlands, Russia, Switzerland, Turkey, rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, and rest of Middle East and Africa.
North America is expected to dominate the market as it comprises a large number of key companies and a huge network of suppliers and manufacturers. The U.S. is expected to dominate the market due to the continuous innovation in drug development in breast cancer treatment, offering new avenues for improved patient outcomes and a brighter future in the fight against this devastating disease. Germany in Europe is expected to dominate the market due to the increasing incidence of breast cancer, which is not only affecting the pharmaceutical sector but also influencing healthcare systems and policies. China in Asia-Pacific is expected to dominate the market due to growing awareness of the importance of hormone therapy in reducing the risk of recurrence, which is leading to its incorporation into standard treatment protocols.
The country section of the report also provides individual market-impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as downstream and upstream value chain analysis, technical trends, Porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, and the impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Breast Cancer Drugs Market Share Analysis
世界の乳がん治療薬市場の競争状況は、競合他社の詳細を提供します。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、世界的なプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性などがあります。提供されている上記のデータ ポイントは、市場に対する会社の重点にのみ関連しています。
世界の乳がん治療薬市場で活動している主要企業としては、F. ホフマン・ラ・ロシュ社、ファイザー社、アストラゼネカ社、ノバルティス社、イーライリリー社、メルク社、サノフィ社、ブリストル・マイヤーズ スクイブ社、エーザイ社、マイラン社（ビアトリス社の子会社）、テバ製薬、協和キリン社、マクロジェニックス社、ギリアド・サイエンシズ社、武田薬品工業株式会社、アッヴィ社などが挙げられます。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL BREAST CANCER DRUGS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 DBMR MARKET POSITION GRID
2.8 MULTIVARIATE MODELLING
2.9 PRODUCT TYPE LIFELINE CURVE
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER'S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 EPIDEMIOLOGY
4.4 PIPELINE ANALYSIS
5 REGULATIONS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 ADVANCEMENT IN DRUGS ASSOCIATED WITH BREAST CANCER TREATMENT
6.1.2 INCREASING INCIDENCE OF BREAST CANCER ACROSS DIFFERENT COUNTRIES
6.1.3 INCREASING DEVELOPMENT IN THE FIELD OF TARGETED THERAPY FOR BREAST CANCER
6.1.4 INCREASING USAGE OF HORMONE THERAPY IN BREAST CANCER TREATMENT
6.1.5 GROWING NUMBER OF SCREENING PROGRAMS RELATED TO BREAST CANCER
6.2 RESTRAINTS
6.2.1 RISING COST OF DRUGS ASSOCIATED WITH CANCER TREATMENT
6.2.2 ADVERSE SIDE EFFECTS AND COMPATIBILITY CONCERNS
6.3 OPPORTUNITIES
6.3.1 GOVERNMENT INITIATIVES AND OTHER FUNDING SOURCES FOR CANCER RESEARCH
6.3.2 INTEGRATION OF ARTIFICIAL INTELLIGENCE (AI) IN DRUG DEVELOPMENT
6.3.3 USAGE OF ADJUVANT THERAPIES
6.4 CHALLENGES
6.4.1 COMPLICATIONS ASSOCIATED WITH CHEMOTHERAPY
6.4.2 LACK IN EARLY DETECTION OF BREAST CANCER
7 GLOBAL BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE
7.1 OVERVIEW
7.2 MEDICATION
7.2.1 ANASTROZOLE (ARIMIDEX)
7.2.2 CYCLOPHOSPHAMIDE (CYTOXAN)
7.2.3 EXEMESTANE (AROMASIN)
7.2.4 LETROZOLE (FEMARA)
7.2.5 OTHERS
7.3 CHEMOTHERAPY
7.3.1 FLUOROURACIL
7.3.2 METHOTREXATE
7.3.3 PACLITAXEL
7.3.4 EPIRUBICIN
7.3.5 DOCETAXEL
7.3.6 OTHERS
7.4 RADIATION THERAPY
7.5 TARGETED THERAPY
7.5.1 PEMBROLIZUMAB
7.5.2 OLAPARIB
7.5.3 LAPROTRECTINIB
7.5.4 ENTRECTINIB
7.5.5 OTHERS
7.6 OTHERS
8 GLOBAL BREAST CANCER DRUGS MARKET, BY STAGES
8.1 OVERVIEW
8.2 STAGE I
8.3 STAGE II
8.4 STAGE 0
8.5 STAGE III
8.6 STAGE IV
9 GLOBAL BREAST CANCER DRUGS MARKET, BY DRUG TYPE
9.1 OVERVIEW
9.2 BRANDED
9.3 GENERIC
10 GLOBAL BREAST CANCER DRUGS MARKET, BY AGE GROUP
10.1 OVERVIEW
10.2 GERIATRIC
10.3 ADULTS
11 GLOBAL BREAST CANCER DRUGS MARKET, BY CANCER TYPE
11.1 OVERVIEW
11.2 INVASIVE DUCTAL CARCINOMA (IDC)
11.3 INVASIVE LOBULAR CARCINOMA (ILC)
11.4 INFLAMMATORY BREAST CANCER
11.5 PAGET’S DISEASE OF THE NIPPLE
11.6 ANGIOSARCOMA OF THE BREAST
11.7 PHYLLODES TUMORS OF THE BREAST
11.8 NONINVASIVE (IN-SITU) TYPES OF BREAST CANCER
11.9 DUCTAL CARCINOMA IN SITU (DCIS)
11.1 LOBULAR CARCINOM AIN SITU (LCIS)
11.11 METASTATIC BREAST CANCER
11.12 OTHERS
12 GLOBAL BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION
12.1 OVERVIEW
12.2 INTRAVENOUS
12.3 ORAL
13 GLOBAL BREAST CANCER DRUGS MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITALS
13.3 CANCER CENTERS
13.4 SPECIALTY CLINICS
13.5 OTHERS
14 GLOBAL BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 HOSPITAL PHARMACY
14.3 RETAIL PHARMACY
14.4 ONLINE PHARMACY
15 GLOBAL BREAST CANCER DRUGS MARKET, BY REGION
15.1 OVERVIEW
15.2 NORTH AMERICA
15.2.1 U.S.
15.2.2 CANADA
15.2.3 MEXICO
15.3 EUROPE
15.3.1 GERMANY
15.3.2 U.K.
15.3.3 ITALY
15.3.4 FRANCE
15.3.5 SPAIN
15.3.6 SWITZERLAND
15.3.7 BELGIUM
15.3.8 NETHERLANDS
15.3.9 RUSSIA
15.3.10 TURKEY
15.3.11 REST OF EUROPE
15.4 ASIA-PACIFIC
15.4.1 JAPAN
15.4.2 AUSTRALIA
15.4.3 SOUTH KOREA
15.4.4 CHINA
15.4.5 INDIA
15.4.6 THAILAND
15.4.7 INDONESIA
15.4.8 MALAYSIA
15.4.9 SINGAPORE
15.4.10 PHILIPPINES
15.4.11 REST OF ASIA-PACIFIC
15.5 SOUTH AMERICA
15.5.1 ARGENTINA
15.5.2 BRAZIL
15.5.3 REST OF SOUTH AMERICA
15.6 MIDDLE EAST AND AFRICA
15.6.1 SOUTH AFRICA
15.6.2 EGYPT
15.6.3 U.A.E.
15.6.4 SAUDI ARABIA
15.6.5 REST OF MIDDLE EAST AND AFRICA
16 GLOBAL BREAST CANCER DRUGS MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: GLOBAL
17 NORTH AMERICA BREAST CANCER DRUGS MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
18 EUROPE BREAST CANCER DRUGS MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: EUROPE
19 ASIA-PACIFIC BREAST CANCER DRUGS MARKET: COMPANY LANDSCAPE
19.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
20 SWOT ANALYSIS
21 COMPANY PROFILES
21.1 F. HOFFMANN-LA ROCHE LTD
21.1.1 COMPANY SNAPSHOT
21.1.2 REVENUE ANALYSIS
21.1.3 COMAPANY SHARE ANALYSIS
21.1.4 PRODUCT PORTFOLIO
21.1.5 RECENT DEVELOPMENTS
21.2 PFIZER INC.
21.2.1 COMPANY SNAPSHOT
21.2.2 REVENUE ANALYSIS
21.2.3 COMAPANY SHARE ANALYSIS
21.2.4 PRODUCT PORTFOLIO
21.2.5 RECENT DEVELOPMENTS
21.3 ASTRAZENECA
21.3.1 COMPANY SNAPSHOT
21.3.2 REVENUE ANALYSIS
21.3.3 COMAPANY SHARE ANALYSIS
21.3.4 PRODUCT PORTFOLIO
21.3.5 RECENT DEVELOPMENT
21.4 NOVARTIS AG
21.4.1 COMPANY SNAPSHOT
21.4.2 REVENUE ANALYSIS
21.4.3 COMAPANY SHARE ANALYSIS
21.4.4 PRODUCT PORTFOLIO
21.4.5 RECENT DEVELOPMENT
21.5 ELI LILLY AND COMPANY
21.5.1 COMPANY SNAPSHOT
21.5.2 REVENUE ANALYSIS
21.5.3 COMAPANY SHARE ANALYSIS
21.5.4 PRODUCT PORTFOLIO
21.5.5 RECENT DEVELOPMENTS
21.6 ABBVIE, INC.
21.6.1 COMPANY SNAPSHOT
21.6.2 REVENUE ANALYSIS
21.6.3 PRODUCT PORTFOLIO
21.6.4 RECENT DEVELOPMENT
21.7 BRISTOL-MYERS SQUIBB COMPANY
21.7.1 COMPANY SNAPSHOT
21.7.2 REVENUE ANALYSIS
21.7.3 PRODUCT PORTFOLIO
21.7.4 RECENT DEVELOPMENT
21.8 EISAI CO., LTD
21.8.1 COMPANY SNAPSHOT
21.8.2 REVENUE ANALYSIS
21.8.3 PRODUCT PORTFOLIO
21.8.4 RECENT DEVELOPMENT
21.9 KYOWA KIRIN CO., LTD
21.9.1 COMPANY SNAPSHOT
21.9.2 REVENUE ANALYSIS
21.9.3 PRODUCT PORTFOLIO
21.9.4 RECENT DEVELOPMENT
21.1 MERCK & CO., INC.
21.10.1 COMPANY SNAPSHOT
21.10.2 REVENUE ANALYSIS
21.10.3 PRODUCT PORTFOLIO
21.10.4 RECENT DEVELOPMENT
21.11 MACROGENICS, INC.
21.11.1 COMPANY SNAPSHOT
21.11.2 REVENUE ANALYSIS
21.11.3 PRODUCT PORTFOLIO
21.11.4 RECENT DEVELOPMENT
21.12 SANOFI
21.12.1 COMPANY SNAPSHOT
21.12.2 REVENUE ANALYSIS
21.12.3 PRODUCT PORTFOLIO
21.12.4 RECENT DEVELOPMENTS
21.13 TEVA PHARMACEUTICAL INDUSTRIES LTD
21.13.1 COMPANY SNAPSHOT
21.13.2 REVENUE ANALYSIS
21.13.3 PRODUCT PORTFOLIO
21.13.4 RECENT DEVELOPMENT
21.14 VIATRIS INC
21.14.1 COMPANY SNAPSHOT
21.14.2 REVENUE ANALYSIS
21.14.3 PRODUCT PORTFOLIO
21.14.4 RECENT DEVELOPMENT
21.15 GILEAD SCIENCES, INC
21.15.1 COMPANY SNAPSHOT
21.15.2 REVENUE ANALYSIS
21.15.3 PRODUCT PORTFOLIO
21.15.4 RECENT DEVELOPMENT
21.16 TAKEDA PHARMACEUTICAL COMPANY LIMITED
21.16.1 COMPANY SNAPSHOT
21.16.2 REVENUE ANALYSIS
21.16.3 PRODUCT PORTFOLIO
21.16.4 RECENT DEVELOPMENT
22 QUESTIONNAIRE
23 RELATED REPORTS
表のリスト
TABLE 1 GLOBAL BREAST CANCER DRUGS MARKET, PIPELINE ANALYSIS
TABLE 2 GLOBAL BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 3 GLOBAL MEDICATION IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 4 GLOBAL MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 5 GLOBAL CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 6 GLOBAL CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 7 GLOBAL RADIATION THERAPY IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 8 GLOBAL TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 9 GLOBAL TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 10 GLOBAL OTHERS IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 11 GLOBAL BREAST CANCER DRUGS MARKET, BY STAGES, 2022-2030 (USD MILLION)
TABLE 12 GLOBAL STAGE I IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 13 GLOBAL STAGE II IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 GLOBAL STAGE 0 IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 GLOBAL STAGE III IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 GLOBAL STAGE IV IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 GLOBAL BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 18 GLOBAL BRANDED IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 GLOBAL GENERIC IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 GLOBAL BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 21 GLOBAL GERIATRIC IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 GLOBAL ADULTS IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 GLOBAL BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 24 GLOBAL INVASIVE DUCTAL CARCINOMA (IDC) IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 GLOBAL INVASIVE LOBULAR CARCINOMA (ILC) IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 GLOBAL INFLAMMATORY BREAST CANCER IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 27 GLOBAL PAGET’S DISEASE OF THE NIPPLE IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 GLOBAL ANGIOSARCOMA OF THE BREAST IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 GLOBAL PHYLLODES TUMORS OF THE BREAST IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 GLOBAL NONINVASIVE (IN SITU) TYPES OF BREAST CANCER IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 GLOBAL DUCTAL CARCINOMA IN SITU (DCIS) IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 32 GLOBAL LOBULAR CARCINOMA IN SITU (LCIS) IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 GLOBAL METASTATIC BREAST CANCER IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 34 GLOBAL OTHERS IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 GLOBAL BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 36 GLOBAL INTRAVENOUS IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 37 GLOBAL ORAL IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 38 GLOBAL BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 39 GLOBAL HOSPITALS IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 GLOBAL CANCER CENTERS IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 41 GLOBAL SPECIALTY CLINICS IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 GLOBAL OTHERS IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 GLOBAL BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION)
TABLE 44 GLOBAL HOSPITAL PHARMACY IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 45 GLOBAL RETAIL PHARMACY IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 GLOBAL ONLINE PHARMACY IN BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 47 GLOBAL BREAST CANCER DRUGS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 48 NORTH AMERICA BREAST CANCER DRUGS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 49 NORTH AMERICA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 50 NORTH AMERICA MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 51 NORTH AMERICA CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 52 NORTH AMERICA TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 53 NORTH AMERICA BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 54 NORTH AMERICA BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 55 NORTH AMERICA BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 56 NORTH AMERICA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 57 NORTH AMERICA BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 58 NORTH AMERICA BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 59 NORTH AMERICA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 60 U.S. BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 61 U.S. MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 62 U.S. CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 63 U.S. TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 64 U.S. BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 65 U.S. BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 66 U.S. BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 67 U.S. BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 68 U.S. BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 69 U.S. BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 70 U.S. BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 71 CANADA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 72 CANADA MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 73 CANADA CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 74 CANADA TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 75 CANADA BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 76 CANADA BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 77 CANADA BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 78 CANADA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 79 CANADA BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 80 CANADA BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 81 CANADA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 82 MEXICO BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 83 MEXICO MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 84 MEXICO CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 85 MEXICO TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 86 MEXICO BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 87 MEXICO BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 88 MEXICO BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 89 MEXICO BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 90 MEXICO BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 91 MEXICO BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 92 MEXICO BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 93 EUROPE BREAST CANCER DRUGS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 94 EUROPE BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 95 EUROPE MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 96 EUROPE CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 97 EUROPE TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 98 EUROPE BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 99 EUROPE BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 100 EUROPE BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 101 EUROPE BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 102 EUROPE BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 103 EUROPE BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 104 EUROPE BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 105 GERMANY BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 106 GERMANY MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 107 GERMANY CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 108 GERMANY TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 109 GERMANY BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 110 GERMANY BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 111 GERMANY BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 112 GERMANY BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 113 GERMANY BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 114 GERMANY BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 115 GERMANY BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 116 U.K. BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 117 U.K. MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 118 U.K. CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 119 U.K. TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 120 U.K. BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 121 U.K. BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 122 U.K. BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 123 U.K. BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 124 U.K. BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 125 U.K. BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 126 U.K. BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 127 ITALY BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 128 ITALY MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 129 ITALY CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 130 ITALY TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 131 ITALY BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 132 ITALY BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 133 ITALY BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 134 ITALY BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 135 ITALY BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 136 ITALY BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 137 ITALY BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 138 FRANCE BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 139 FRANCE MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 140 FRANCE CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 141 FRANCE TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 142 FRANCE BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 143 FRANCE BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 144 FRANCE BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 145 FRANCE BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 146 FRANCE BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 147 FRANCE BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 148 FRANCE BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 149 SPAIN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 150 SPAIN MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 151 SPAIN CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 152 SPAIN TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 153 SPAIN BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 154 SPAIN BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 155 SPAIN BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 156 SPAIN BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 157 SPAIN BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 158 SPAIN BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 159 SPAIN BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 160 SWITZERLAND BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 161 SWITZERLAND MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 162 SWITZERLAND CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 163 SWITZERLAND TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 164 SWITZERLAND BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 165 SWITZERLAND BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 166 SWITZERLAND BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 167 SWITZERLAND BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 168 SWITZERLAND BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 169 SWITZERLAND BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 170 SWITZERLAND BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 171 BELGIUM BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 172 BELGIUM MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 173 BELGIUM CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 174 BELGIUM TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 175 BELGIUM BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 176 BELGIUM BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 177 BELGIUM BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 178 BELGIUM BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 179 BELGIUM BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 180 BELGIUM BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 181 BELGIUM BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 182 NETHERLANDS BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 183 NETHERLANDS MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 184 NETHERLANDS CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 185 NETHERLANDS TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 186 NETHERLANDS BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 187 NETHERLANDS BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 188 NETHERLANDS BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 189 NETHERLANDS BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 190 NETHERLANDS BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 191 NETHERLANDS BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 192 NETHERLANDS BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 193 RUSSIA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 194 RUSSIA MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 195 RUSSIA CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 196 RUSSIA TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 197 RUSSIA BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 198 RUSSIA BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 199 RUSSIA BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 200 RUSSIA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 201 RUSSIA BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 202 RUSSIA BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 203 RUSSIA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 204 TURKEY BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 205 TURKEY MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 206 TURKEY CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 207 TURKEY TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 208 TURKEY BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 209 TURKEY BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 210 TURKEY BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 211 TURKEY BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 212 TURKEY BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 213 TURKEY BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 214 TURKEY BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 215 REST OF EUROPE BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 216 ASIA-PACIFIC BREAST CANCER DRUGS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 217 ASIA-PACIFIC BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 218 ASIA-PACIFIC MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 219 ASIA-PACIFIC CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 220 ASIA-PACIFIC TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 221 ASIA-PACIFIC BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 222 ASIA-PACIFIC BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 223 ASIA-PACIFIC BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 224 ASIA-PACIFIC BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 225 ASIA-PACIFIC BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 226 ASIA-PACIFIC BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 227 ASIA-PACIFIC BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 228 JAPAN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 229 JAPAN MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 230 JAPAN CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 231 JAPAN TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 232 JAPAN BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 233 JAPAN BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 234 JAPAN BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 235 JAPAN BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 236 JAPAN BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 237 JAPAN BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 238 JAPAN BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 239 AUSTRALIA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 240 AUSTRALIA MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 241 AUSTRALIA CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 242 AUSTRALIA TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 243 AUSTRALIA BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 244 AUSTRALIA BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 245 AUSTRALIA BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 246 AUSTRALIA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 247 AUSTRALIA BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 248 AUSTRALIA BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 249 AUSTRALIA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 250 SOUTH KOREA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 251 SOUTH KOREA MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 252 SOUTH KOREA CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 253 SOUTH KOREA TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 254 SOUTH KOREA BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 255 SOUTH KOREA BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 256 SOUTH KOREA BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 257 SOUTH KOREA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 258 SOUTH KOREA BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 259 SOUTH KOREA BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 260 SOUTH KOREA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 261 CHINA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 262 CHINA MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 263 CHINA CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 264 CHINA TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 265 CHINA BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 266 CHINA BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 267 CHINA BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 268 CHINA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 269 CHINA BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 270 CHINA BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 271 CHINA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 272 INDIA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 273 INDIA MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 274 INDIA CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 275 INDIA TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 276 INDIA BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 277 INDIA BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 278 INDIA BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 279 INDIA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 280 INDIA BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 281 INDIA BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 282 INDIA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 283 THAILAND BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 284 THAILAND MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 285 THAILAND CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 286 THAILAND TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 287 THAILAND BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 288 THAILAND BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 289 THAILAND BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 290 THAILAND BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 291 THAILAND BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 292 THAILAND BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 293 THAILAND BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 294 INDONESIA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 295 INDONESIA MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 296 INDONESIA CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 297 INDONESIA TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 298 INDONESIA BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 299 INDONESIA BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 300 INDONESIA BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 301 INDONESIA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 302 INDONESIA BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 303 INDONESIA BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 304 INDONESIA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 305 MALAYSIA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 306 MALAYSIA MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 307 MALAYSIA CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 308 MALAYSIA TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 309 MALAYSIA BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 310 MALAYSIA BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 311 MALAYSIA BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 312 MALAYSIA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 313 MALAYSIA BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 314 MALAYSIA BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 315 MALAYSIA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 316 SINGAPORE BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 317 SINGAPORE MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 318 SINGAPORE CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 319 SINGAPORE TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 320 SINGAPORE BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 321 SINGAPORE BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 322 SINGAPORE BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 323 SINGAPORE BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 324 SINGAPORE BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 325 SINGAPORE BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 326 SINGAPORE BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 327 PHILIPPINES BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 328 PHILIPPINES MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 329 PHILIPPINES CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 330 PHILIPPINES TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 331 PHILIPPINES BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 332 PHILIPPINES BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 333 PHILIPPINES BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 334 PHILIPPINES BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 335 PHILIPPINES BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 336 PHILIPPINES BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 337 PHILIPPINES BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 338 REST OF ASIA-PACIFIC BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 339 SOUTH AMERICA BREAST CANCER DRUGS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 340 SOUTH AMERICA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 341 SOUTH AMERICA MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 342 SOUTH AMERICA CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 343 SOUTH AMERICA TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 344 SOUTH AMERICA BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 345 SOUTH AMERICA BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 346 SOUTH AMERICA BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 347 SOUTH AMERICA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 348 SOUTH AMERICA BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 349 SOUTH AMERICA BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 350 SOUTH AMERICA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 351 ARGENTINA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 352 ARGENTINA MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 353 ARGENTINA CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 354 ARGENTINA TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 355 ARGENTINA BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 356 ARGENTINA BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 357 ARGENTINA BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 358 ARGENTINA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 359 ARGENTINA BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 360 ARGENTINA BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 361 ARGENTINA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 362 BRAZIL BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 363 BRAZIL MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 364 BRAZIL CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 365 BRAZIL TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 366 BRAZIL BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 367 BRAZIL BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 368 BRAZIL BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 369 BRAZIL BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 370 BRAZIL BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 371 BRAZIL BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 372 BRAZIL BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 373 REST OF SOUTH AMERICA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 374 MIDDLE EAST AND AFRICA BREAST CANCER DRUGS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 375 MIDDLE EAST AND AFRICA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 376 MIDDLE EAST AND AFRICA MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 377 MIDDLE EAST AND AFRICA CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 378 MIDDLE EAST AND AFRICA TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 379 MIDDLE EAST AND AFRICA BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 380 MIDDLE EAST AND AFRICA BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 381 MIDDLE EAST AND AFRICA BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 382 MIDDLE EAST AND AFRICA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 383 MIDDLE EAST AND AFRICA BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 384 MIDDLE EAST AND AFRICA BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 385 MIDDLE EAST AND AFRICA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 386 SOUTH AFRICA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 387 SOUTH AFRICA MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 388 SOUTH AFRICA CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 389 SOUTH AFRICA TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 390 SOUTH AFRICA BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 391 SOUTH AFRICA BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 392 SOUTH AFRICA BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 393 SOUTH AFRICA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 394 SOUTH AFRICA BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 395 SOUTH AFRICA BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 396 SOUTH AFRICA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 397 EGYPT BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 398 EGYPT MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 399 EGYPT CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 400 EGYPT TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 401 EGYPT BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 402 EGYPT BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 403 EGYPT BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 404 EGYPT BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 405 EGYPT BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 406 EGYPT BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 407 EGYPT BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 408 U.A.E. BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 409 U.A.E. MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 410 U.A.E. CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 411 U.A.E. TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 412 U.A.E. BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 413 U.A.E. BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 414 U.A.E. BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 415 U.A.E. BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 416 U.A.E. BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 417 U.A.E. BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 418 U.A.E. BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 419 SAUDI ARABIA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 420 SAUDI ARABIA MEDICATION IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 421 SAUDI ARABIA CHEMOTHERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 422 SAUDI ARABIA TARGETED THERAPY IN BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 423 SAUDI ARABIA BREAST CANCER DRUGS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 424 SAUDI ARABIA BREAST CANCER DRUGS MARKET, BY STAGES, 2021-2030 (USD MILLION)
TABLE 425 SAUDI ARABIA BREAST CANCER DRUGS MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)
TABLE 426 SAUDI ARABIA BREAST CANCER DRUGS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 427 SAUDI ARABIA BREAST CANCER DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)
TABLE 428 SAUDI ARABIA BREAST CANCER DRUGS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 429 SAUDI ARABIA BREAST CANCER DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 430 REST OF MIDDLE EAST AND AFRICA BREAST CANCER DRUGS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
図表一覧
FIGURE 1 GLOBAL BREAST CANCER DRUGS MARKET: SEGMENTATION
FIGURE 2 GLOBAL BREAST CANCER DRUGS MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL BREAST CANCER DRUGS MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL BREAST CANCER DRUGS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL BREAST CANCER DRUGS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL BREAST CANCER DRUGS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL BREAST CANCER DRUGS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 GLOBAL BREAST CANCER DRUGS MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 GLOBAL BREAST CANCER DRUGS MARKET: SEGMENTATION
FIGURE 10 NORTH AMERICA REGION IS EXPECTED TO DOMINATE THE GLOBAL BREAST CANCER DRUGS MARKET AND ASIA-PACIFIC REGION GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 11 RISING INCIDENCE OF BREAST CANCER IS DRIVING THE GROWTH OF GLOBAL BREAST CANCER DRUGS MARKET IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 12 MEDICATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL BREAST CANCER DRUGS MARKET IN 2023 & 2030
FIGURE 13 NORTH AMERICA IS THE FASTEST-GROWING MARKET FOR BREAST CANCER DRUGS MANUFACTURERS IN THE FORECAST PERIOD OF 2023 TO 2030
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL BREAST CANCER DRUGS MARKET
FIGURE 15 GLOBAL BREAST CANCER DRUGS MARKET: BY PRODUCT TYPE, 2022
FIGURE 16 GLOBAL BREAST CANCER DRUGS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 17 GLOBAL BREAST CANCER DRUGS MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 18 GLOBAL BREAST CANCER DRUGS MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 19 GLOBAL BREAST CANCER DRUGS MARKET: BY STAGES , 2022
FIGURE 20 GLOBAL BREAST CANCER DRUGS MARKET: BY STAGES, 2023-2030 (USD MILLION)
FIGURE 21 GLOBAL BREAST CANCER DRUGS MARKET: BY STAGES, CAGR (2023-2030)
FIGURE 22 GLOBAL BREAST CANCER DRUGS MARKET: BY STAGES, LIFELINE CURVE
FIGURE 23 GLOBAL BREAST CANCER DRUGS MARKET: BY DRUG TYPE, 2022
FIGURE 24 GLOBAL BREAST CANCER DRUGS MARKET: BY DRUG TYPE, 2023-2030 (USD MILLION)
FIGURE 25 GLOBAL BREAST CANCER DRUGS MARKET: BY DRUG TYPE, CAGR (2023-2030)
FIGURE 26 GLOBAL BREAST CANCER DRUGS MARKET: BY DRUG TYPE, LIFELINE CURVE
FIGURE 27 GLOBAL BREAST CANCER DRUGS MARKET: BY AGE GROUP, 2022
FIGURE 28 GLOBAL BREAST CANCER DRUGS MARKET: BY AGE GROUP, 2023-2030 (USD MILLION)
FIGURE 29 GLOBAL BREAST CANCER DRUGS MARKET: BY AGE GROUP, CAGR (2023-2030)
FIGURE 30 GLOBAL BREAST CANCER DRUGS MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 31 GLOBAL BREAST CANCER DRUGS MARKET: BY CANCER TYPE, 2022
FIGURE 32 GLOBAL BREAST CANCER DRUGS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION)
FIGURE 33 GLOBAL BREAST CANCER DRUGS MARKET: BY CANCER TYPE, CAGR (2023-2030)
FIGURE 34 GLOBAL BREAST CANCER DRUGS MARKET: BY T CANCER TYPE, LIFELINE CURVE
FIGURE 35 GLOBAL BREAST CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2022
FIGURE 36 GLOBAL BREAST CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)
FIGURE 37 GLOBAL BREAST CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)
FIGURE 38 GLOBAL BREAST CANCER DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 39 GLOBAL BREAST CANCER DRUGS MARKET: BY END USER, 2022
FIGURE 40 GLOBAL BREAST CANCER DRUGS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 41 GLOBAL BREAST CANCER DRUGS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 42 GLOBAL BREAST CANCER DRUGS MARKET: BY END USER, LIFELINE CURVE
FIGURE 43 GLOBAL BREAST CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 44 GLOBAL BREAST CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 45 GLOBAL BREAST CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 46 GLOBAL BREAST CANCER DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 47 GLOBAL BREAST CANCER DRUGS MARKET: SNAPSHOT (2022)
FIGURE 48 GLOBAL BREAST CANCER DRUGS MARKET: COMPANY SHARE 2022 (%)
FIGURE 49 NORTH AMERICA BREAST CANCER DRUGS MARKET: COMPANY SHARE 2022 (%)
FIGURE 50 EUROPE BREAST CANCER DRUGS MARKET: COMPANY SHARE 2022 (%)
FIGURE 51 AISA-PACIFIC BREAST CANCER DRUGS MARKET: COMPANY SHARE 2022 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
